Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Famotidine  COVID-19 treatment studies for Famotidine  C19 studies: Famotidine  Famotidine   Select treatmentSelect treatmentTreatmentsTreatments
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta
Lactoferrin Meta

Other Treatments Global Adoption
 
    
  
Famotidine for COVID-19
25 studies from 210 scientists
92,443 patients in 10 countries
Statistically significant improvement for mortality, hospitalization, recovery, and viral clearance.
13 studies from 13 independent teams in 6 countries show statistically significant improvements in isolation.
COVID-19 Famotidine studies. Dec 2022. c19early.org/fm
0 0.5 1 1.5+ All studies 15% With exclusions 17% Mortality 17% Hospitalization 15% Recovery 10% Cases 0% Viral clearance 13% RCTs 27% RCT mortality 15% Prophylaxis 13% Early 48% Late 12% Favorsfamotidine Favorscontrol
Famotidine COVID-19 studies. Recent:
Chowdhury
Loucera.
Submit updates/corrections.
Dec 2
Covid Analysis (Preprint) (meta analysis) Famotidine for COVID-19: real-time meta analysis of 25 studies
Statistically significant improvements are seen for mortality, hospitalization, recovery, and viral clearance. 13 studies from 13 independent teams in 6 different countries show statistically significant improvements in isolation (8 for..
Aug 16
Chowdhury et al., World Journal of Clinical Cases, doi:10.12998/wjcc.v10.i23.8170 Role of H2 receptor blocker famotidine over the clinical recovery of COVID-19 patients: A randomized controlled trial
16% lower mortality [p=0.53], 9% shorter ICU admission [p=0.33], 33% faster improvement [p<0.0001], and 7% faster recovery [p=0.14]. RCT 208 ICU patients in Bangladesh, showing improved recovery with famotidine. Famotidine 40mg (<60kg) or 60mg every 8 hours.
Aug 16
Loucera et al., medRxiv, doi:10.1101/2022.08.14.22278751 (Preprint) Real-world evidence with a retrospective cohort of 15,968 Andalusian COVID-19 hospitalized patients suggests 21 new effective treatments and one drug that increases death risk
18% lower mortality [p=0.25]. Retrospective 15,968 COVID-19 hospitalized patients in Spain, showing lower mortality with existing use of several medications including metformin, HCQ, aspirin, vitamin D, vitamin C, and budesonide.
May 13
Zangeneh et al., Obesity Medicine, doi:10.1016/j.obmed.2022.100420 Survival analysis based on body mass index in patients with Covid-19 admitted to the intensive care unit of Amir Al-Momenin Hospital in Arak – 2021
39% lower mortality [p=0.01]. Retrospective 193 ICU patients in Iran, showing lower mortality with famotidine treatment.
Mar 29
MacFadden et al., Open Forum Infectious Diseases, doi:10.1093/ofid/ofac156 Screening Large Population Health Databases for Potential COVID-19 Therapeutics: A Pharmacopeia-Wide Association Study (PWAS) of Commonly Prescribed Medications
7% fewer cases [p=0.16]. Retrospective 26,121 cases and 2,369,020 controls ≥65yo in Canada, showing no significant differences in cases with chronic use of famotidine.
Feb 28
Siraj et al., Indian Journal of Clinical Practice, 32:9 Efficacy of Various Treatment Modalities on Patient-related Outcome in Hospitalized COVID-19 Patients – A Retrospective Study
36% lower mortality [p=0.002]. Retrospective 1,000 COVID+ hospitalized patients in India, showing lower mortality with famotidine and remdesivir in multivariable logistic regression.
Feb 24
Kory et al., Journal of Clinical Medicine Research, doi:10.14740/jocmr4658 (Review) “MATH+” Multi-Modal Hospital Treatment Protocol for COVID-19 Infection: Clinical and Scientific Rationale
Review of the data supporting the MATH+ hospital treatment protocol for COVID-19.
Feb 20
Pahwani et al., Cureus, doi:10.7759/cureus.22404 Efficacy of Oral Famotidine in Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2
11% lower mortality [p=1], 12% lower ventilation [p=0.73], 10% lower ICU admission [p=0.86], and 17% shorter hospitalization [p<0.0001]. RCT with 89 famotidine and 89 control patients in Pakistan, showing faster recovery but no significant difference in mortality. 40mg oral famotidine daily.
Feb 10
Brennan et al., Gut, doi:10.1136/gutjnl-2022-326952 Oral famotidine versus placebo in non-hospitalised patients with COVID-19: a randomised, double-blind, data-intense, phase 2 clinical trial
48% improved recovery [p=0.23]. Small RCT with 27 famotidine and 28 placebo patients, showing improved recovery with treatment. Recovery was faster with treatment for 14 of 16 symptoms. There was no mortality or hospitalization. NCT04724720.
Jan 17
Park et al., BMC Pharmacology and Toxicology, doi:10.1186/s40360-022-00549-7 Comparative risk of incidence and clinical outcomes of COVID-19 among proton pump inhibitor and histamine-2 receptor antagonist short-term users: a nationwide retrospective cohort study
Retrospective 62,117 histamine-2 receptor antagonist users in South Korea, showing lower risk of COVID-19 with histamine-2 receptor antagonist use (famotidine, ranitidine, nizatidine, lafutidine, and cimetidine), without statistical signi..
Dec 31
2021
Wallace et al., BMJ Open, doi:10.1136/bmjopen-2021-050051 Association of the patterns of use of medications with mortality of COVID-19 infection: a hospital-based observational study
11% higher mortality [p=0.33]. Retrospective 9,532 hospitalized COVID+ veterans in the USA, showing no significant difference in mortality with famotidine use. The study provides results for use before, after, and before+after. Before+after should more accurately repre..
Oct 31
2021
Wagner et al., American Journal of Gastroenterology, doi:10.14309/01.ajg.0000779364.64867.ec Famotidine versus Pantoprazole Use and Clinical Outcomes in Patients Hospitalized With COVID-19: A Retrospective Study
70% lower mortality [p<0.0001]. Retrospective 2,184 hospitalized patients in the USA, 638 treated with famotidine, showing lower mortality with treatment.
Oct 31
2021
Stolow et al., American Journal of Gastroenterology, doi:10.14309/01.ajg.0000778736.01714.cd A Retrospective Review: Famotidine Use Is Not Associated With Improved Outcomes in Hospitalized Patients With COVID-19
519% higher mortality [p=0.001] and 2390% higher ICU admission [p=0.001]. Retrospective 489 COVID+ hospitalized patients in the USA, showing higher mortality with famotidine treatment.
Oct 25
2021
Razjouyan et al., Nicotine & Tobacco Research, doi:10.1093/ntr/ntab223 Smoking Status and Factors associated with COVID-19 In-Hospital Mortality among US Veterans
27% lower mortality [p=0.006]. Retrospective 10,074 veterens in the USA, showing lower mortality with existing famotidine use.
Oct 11
2021
Kuno et al., Journal of Medical Virology, doi:10.1002/jmv.27375 The association between famotidine and in‐hospital mortality of patients with COVID‐19
no change in mortality [p=0.97]. PSM retrospective 9,565 COVID-19 hospitalized patients in the USA, 1,593 receiving famotidine, showing no significant difference in mortality.
Oct 1
2021
Fung et al., PLoS ONE, doi:10.1371/journal.pone.0266922 (date from earlier preprint) Effect of common maintenance drugs on the risk and severity of COVID-19 in elderly patients
no change in mortality [p=1], 6% lower hospitalization [p=0.0002], and 12% more cases [p<0.0001]. Retrospective database analysis of 374,229 patients in the USA, showing higher cases, lower hospitalizations, and no change in mortality with famotidine use.
Jul 12
2021
Taşdemir et al., Konuralp Tıp Dergisi, doi:10.18521/ktd.935888 Famotidine in COVID-19 treatment
45% lower mortality [p=0.29], 37% lower ICU admission [p=0.36], 18% shorter hospitalization [p=0.003], and 20% faster recovery [p=0.04]. Retrospective 179 hospitalized patients in Turkey, 85 treated with famotidine and 94 treated with pantoprazole, showing faster recovery with famotidine in unadjusted results.
Apr 30
2021
Elhadi et al., PLOS ONE, doi:10.1371/journal.pone.0251085 Epidemiology, outcomes, and utilization of intensive care unit resources for critically ill COVID-19 patients in Libya: A prospective multi-center cohort study
7% lower mortality [p=0.57]. Prospective study of 465 COVID-19 ICU patients in Libya showing no significant differences with treatment.
Apr 30
2021
Cheung et al., Gastroenterology, doi:10.1053/j.gastro.2020.05.098 Association Between Famotidine Use and COVID-19 Severity in Hong Kong: A Territory-wide Study
34% higher severe cases [p=0.72]. Retrospective 952 COVID-19 patients in Hong Kong, showing no significant difference in severe disease with famotidine use.
Apr 27
2021
Samimagham et al., Research Square, doi:10.21203/rs.3.rs-462937/v1 (Preprint) The Efficacy of Famotidine in improvement of outcomes in Hospitalized COVID-19 Patients: A phase III randomised clinical trial
33% shorter hospitalization [p=0.04] and no change in recovery [p=1]. Very small RCT with 20 patients in Iran, showing shorter hospitalization time with famotidine treatment. There was no mortality or ICU admission. Famotidine 160mg four times a day. IRCT20200509047364N2.
Mar 31
2021
Mura et al., Signal Transduction and Targeted Therapy, doi:10.1038/s41392-021-00689-y (date from earlier preprint) Real-world evidence for improved outcomes with histamine antagonists and aspirin in 22,560 COVID-19 patients
21% lower mortality [p=0.02]. PSM retrospective TriNetX database analysis of 1,379 severe COVID-19 patients requiring respiratory support, showing lower mortality with aspirin (not reaching statistical significance) and famotidine, and improved results from the combin..
Mar 8
2021
Loffredo et al., Scientific Reports, doi:10.1038/s41598-021-84782-w (In Vitro) The in-vitro effect of famotidine on SARS-CoV-2 proteases and virus replication
In Vitro study showing that famotidine does not bind or inhibit 3CLpro and PLpro, and no direct antiviral activity was observed with concentrations up to 200µM in Vero E6 and A549 cells.
Feb 28
2021
Yeramaneni et al., Gastroenterology, doi:10.1053/j.gastro.2020.10.011 Famotidine Use Is Not Associated With 30-day Mortality: A Coarsened Exact Match Study in 7158 Hospitalized Patients With Coronavirus Disease 2019 From a Large Healthcare System
51% lower mortality [p=0.22]. Retrospective 7,158 hospitalized COVID-19 patients in the USA, showing higher risk or mortality with in-hospital famotidine use and lower risk with pre-existing use, without statistical significance in both cases.
Jan 20
2021
Balouch et al., Journal of Voice, doi:10.1016/j.jvoice.2021.01.007 Role of Famotidine and Other Acid Reflux Medications for SARS-CoV-2: A Pilot Study
22% fewer symptomatic cases [p=0.49] and 37% faster recovery [p=0.32]. Survey of 307 patients in the USA, showing no significant difference in COVID-19 cases with famotidine use.
Dec 4
2020
Zhou et al., Gut, doi:10.1136/gutjnl-2020-323668 Proton pump inhibitor or famotidine use and severe COVID-19 disease: a propensity score-matched territory-wide study
81% higher severe cases [p=0.0001]. Retrospective 4,445 COVID+ patients in China, showing higher risk of combined death/intubation/ICU with famotidine treatment.
Sep 24
2020
Shoaibi et al., American Journal of Gastroenterology, doi:10.14309/ajg.0000000000001153 (date from earlier preprint) Comparative Effectiveness of Famotidine in Hospitalized COVID-19 Patients
3% higher mortality [p=0.67] and 3% higher combined mortality/ICU admission [p=0.62]. Retrospective 1,816 famotidine users and 26,820 non-users hospitalized for COVID-19 in the USA, showing no significant differences with treatment.
Aug 26
2020
Mather et al., American Journal of Gastroenterology, doi:10.14309/ajg.0000000000000832 Impact of Famotidine Use on Clinical Outcomes of Hospitalized Patients With COVID-19
61% lower mortality [p=0.004] and 50% lower combined mortality/intubation [p=0.003]. PSM retrospective 878 hospitalized patients in the USA, 83 with existing famotidine use, showing significantly lower mortality with treatment.
May 21
2020
Freedberg et al., Gastroenterology, doi:10.1053/j.gastro.2020.05.053 Famotidine Use Is Associated With Improved Clinical Outcomes in Hospitalized COVID-19 Patients: A Propensity Score Matched Retrospective Cohort Study
57% lower combined mortality/intubation [p=0.02]. PSM retrospective 1,620 hospitalized patients in the USA, 84 with existing famotidine use, showing lower risk of combined death/intubation with treatment.
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.
Submit